| scholarly article | Q13442814 |
| P356 | DOI | 10.1055/S-0035-1562947 |
| P698 | PubMed publication ID | 26378644 |
| P50 | author | Quentin M Anstee | Q42834905 |
| P2093 | author name string | Christopher P Day | |
| P2860 | cites work | Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2 | Q57012027 |
| P433 | issue | 3 | |
| P921 | main subject | liver disease | Q929737 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| fatty liver disease | Q6058862 | ||
| P304 | page(s) | 270-290 | |
| P577 | publication date | 2015-08-01 | |
| P1433 | published in | Seminars in Liver Disease | Q15724477 |
| P1476 | title | The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2 | |
| P478 | volume | 35 |
| Q38620897 | (-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis related genes in non-alcoholic fatty liver disease |
| Q57494349 | A systematic review of the present and future of non-alcoholic fatty liver disease |
| Q92255891 | Anti-NASH Drug Development Hitches a Lift on PPAR Agonism |
| Q97073601 | Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events |
| Q61798368 | Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population |
| Q90734876 | Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review |
| Q98612724 | Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge |
| Q47949339 | Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study |
| Q54219671 | Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study. |
| Q38845683 | Concise Review: Current Status and Future Directions on Research Related to Nonalcoholic Fatty Liver Disease |
| Q87889291 | Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers |
| Q93028935 | Fatty Liver and the Forensic Pathologist |
| Q91557675 | From NASH to HCC: current concepts and future challenges |
| Q37146192 | Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review |
| Q33778556 | Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART). |
| Q45067817 | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention |
| Q58554683 | HSD17B13 is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non-Alcoholic Fatty Liver Disease |
| Q28074455 | How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease? |
| Q45061974 | Human germline hedgehog pathway mutations predispose to fatty liver. |
| Q48183802 | Inorganic arsenic causes fatty liver and interacts with ethanol to cause alcoholic liver disease in zebrafish |
| Q37457316 | Mea6 controls VLDL transport through the coordinated regulation of COPII assembly |
| Q92192093 | Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma |
| Q89659860 | NAFLD Preclinical Models: More than a Handful, Less of a Concern? |
| Q88306083 | NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD |
| Q39393326 | New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). |
| Q33789868 | Non-alcoholic fatty liver disease: An expanded review |
| Q36796030 | Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance |
| Q96954178 | Nonalcoholic fatty liver disease and cardiovascular disease phenotypes |
| Q42695154 | Nonalcoholic fatty liver disease: Evolving paradigms. |
| Q97425388 | Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation |
| Q35928495 | Pathogenesis of nonalcoholic steatohepatitis |
| Q50207491 | Polymorphism of receptor-type tyrosine-protein phosphatase delta gene in the development of non-alcoholic fatty liver disease |
| Q64288202 | Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease |
| Q88524844 | Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease |
| Q38687132 | Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity |
| Q40528724 | Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study |
| Q35996623 | Status of hepatic DNA methylome predetermines and modulates the severity of non-alcoholic fatty liver injury in mice |
| Q57066897 | The Genetics of Clinical Liver Diseases: Insight into the E167K Variant |
| Q26744380 | The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background |
| Q86432032 | Time to Abandon NASH? |
| Q37643487 | Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans |
| Q42695159 | Treatment options for alcoholic and non-alcoholic fatty liver disease: A review |
| Q40153908 | Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study |
Search more.